Experimental drug improves ebola patients’ condition

Market Watch – by Joseph Adinolfi

Two U.S. citizens who contracted the ebola virus in Liberia have showed signs of recovery after receiving an experimental treatment called ZMapp, which was developed by Mapp Biopharmaceutical Inc., according to CNN.

The medicine is a “three-mouse monoclonal antibody,” which means that antibodies were harvested from mice exposed to the virus, CNN reported. These antibodies in turn can boost the human immune system’s ability to fight off the virus.  

The treatment had not been used on humans before, but had shown promise in experiments with monkeys, said CNN.

One of the patients, Dr. Kent Brantly, received his first dose of the medication after being ill for 9 days. He was reportedly near death at the time he received the dose, but recovered dramatically within hours of it being administered. One doctor called his recovery “miraculous,” CNN reported.

Brantly was flown back to the U.S. on a Gulfstream air ambulance jet and is receiving treatment at a hospital in Atlanta, according to The Wall Street Journal. The second patient, Nancy Writebol, is expected to arrive back in the U.S. Tuesday.

Typically, the process for getting the Food and Drug Administration’s approval to use an experimental drug is arduous and time-consuming, but both Brantly and Writebol received the drug within seven to 10 days of exposure to the virus. A source quoted by CNN said the expedited approval was “highly unusual,” and was likely allowed by the FDA’s “compassionate use” regulation.

“Compassionate use” sanctions the administering of experimental drugs outside of a clinical trial to patients with a dire prognosis.

–Joseph Adinolfi


4 thoughts on “Experimental drug improves ebola patients’ condition

  1. From the CNN report: “On July 30, the Defense Threat Reduction Agency, an arm of the . . . .

    (get this) “military responsible” . . .

    for any chemical, “biological”, radiological, nuclear and high-yield explosive threats, . . .

    allotted additional funding to MAPP Biopharmaceutical due to “promising results.”

    Right there you have it.

    Military responsible for any biological threats alloted funding = Problem – Reaction – Solution
    . . .

  2. Exactly, Ed! Why did they have to take him back to the U.S. if they already had an experimental drug that supposedly worked? Why couldn’t they just give him the drug there in Africa?

  3. So Mapp Biopharmaceutical Inc. is chosen to be the next super rich company? Like Haliburton, Silverstein and Lowy, Dupont……etc etc ad infinitum? And probably a rival body count like the others as well.

Join the Conversation

Your email address will not be published.